South Korea · Delayed Price · Currency is KRW Remed Statistics
Total Valuation
Remed has a market cap or net worth of KRW 80.79 billion. The enterprise value is 77.80 billion.
| Market Cap | 80.79B |
| Enterprise Value | 77.80B |
Important Dates
The next estimated earnings date is Wednesday, August 26, 2026.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Remed has 29.76 million shares outstanding. The number of shares has decreased by -2.77% in one year.
| Current Share Class | 29.76M |
| Shares Outstanding | 29.76M |
| Shares Change (YoY) | -2.77% |
| Shares Change (QoQ) | -0.96% |
| Owned by Insiders (%) | 37.49% |
| Owned by Institutions (%) | 0.16% |
| Float | 18.60M |
Valuation Ratios
The trailing PE ratio is 57.30.
| PE Ratio | 57.30 |
| Forward PE | n/a |
| PS Ratio | 2.99 |
| PB Ratio | 2.02 |
| P/TBV Ratio | 2.20 |
| P/FCF Ratio | 57.00 |
| P/OCF Ratio | 29.78 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.98, with an EV/FCF ratio of 54.89.
| EV / Earnings | 37.95 |
| EV / Sales | 2.88 |
| EV / EBITDA | 22.98 |
| EV / EBIT | 39.84 |
| EV / FCF | 54.89 |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.09 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 1.75 |
| Debt / FCF | 4.18 |
| Interest Coverage | 2.57 |
Financial Efficiency
Return on equity (ROE) is 3.02% and return on invested capital (ROIC) is 5.04%.
| Return on Equity (ROE) | 3.02% |
| Return on Assets (ROA) | 2.26% |
| Return on Invested Capital (ROIC) | 5.04% |
| Return on Capital Employed (ROCE) | 4.32% |
| Weighted Average Cost of Capital (WACC) | 8.25% |
| Revenue Per Employee | 310.95M |
| Profits Per Employee | 23.57M |
| Employee Count | 87 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.60 |
Taxes
In the past 12 months, Remed has paid 119.81 million in taxes.
| Income Tax | 119.81M |
| Effective Tax Rate | 8.73% |
Stock Price Statistics
The stock price has decreased by -16.92% in the last 52 weeks. The beta is 0.68, so Remed's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -16.92% |
| 50-Day Moving Average | 2,783.10 |
| 200-Day Moving Average | 2,975.83 |
| Relative Strength Index (RSI) | 45.77 |
| Average Volume (20 Days) | 59,930 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Remed had revenue of KRW 27.05 billion and earned 2.05 billion in profits. Earnings per share was 47.38.
| Revenue | 27.05B |
| Gross Profit | 15.10B |
| Operating Income | 1.95B |
| Pretax Income | 1.37B |
| Net Income | 2.05B |
| EBITDA | 3.39B |
| EBIT | 1.95B |
| Earnings Per Share (EPS) | 47.38 |
Balance Sheet
The company has 10.55 billion in cash and 5.93 billion in debt, with a net cash position of 4.62 billion or 155.31 per share.
| Cash & Cash Equivalents | 10.55B |
| Total Debt | 5.93B |
| Net Cash | 4.62B |
| Net Cash Per Share | 155.31 |
| Equity (Book Value) | 39.94B |
| Book Value Per Share | 1,287.10 |
| Working Capital | 17.98B |
Cash Flow
In the last 12 months, operating cash flow was 2.71 billion and capital expenditures -1.29 billion, giving a free cash flow of 1.42 billion.
| Operating Cash Flow | 2.71B |
| Capital Expenditures | -1.29B |
| Depreciation & Amortization | 1.43B |
| Net Borrowing | 413.25M |
| Free Cash Flow | 1.42B |
| FCF Per Share | 47.64 |
Margins
Gross margin is 55.80%, with operating and profit margins of 7.22% and 7.58%.
| Gross Margin | 55.80% |
| Operating Margin | 7.22% |
| Pretax Margin | 5.07% |
| Profit Margin | 7.58% |
| EBITDA Margin | 12.51% |
| EBIT Margin | 7.22% |
| FCF Margin | 5.24% |
Dividends & Yields
Remed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.77% |
| Shareholder Yield | 2.77% |
| Earnings Yield | 2.54% |
| FCF Yield | 1.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 8, 2023. It was a forward split with a ratio of 5.
| Last Split Date | Dec 8, 2023 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Remed has an Altman Z-Score of 5.52 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.52 |
| Piotroski F-Score | 5 |